Alyssa Shell Tilhou, MD, PhD
Assistant Professor, Family Medicine
Biography
Dr. Tilhou is a family physician, addiction specialist and health services researcher in the Department of Family Medicine at Boston Medical Center. She is also the department’s Research Director. Her research focuses on access and utilization of primary care and substance use services in low-income populations. Dr. Tilhou completed her medical education and doctorate in Population Health Sciences at the University of Texas Medical Branch, residency in family medicine at the Mountain Area Health Education Center in Asheville, NC, and a fellowship in Addiction Medicine at the University of Wisconsin. She is supported by a K08 from the National Institute on Drug Abuse. Other recent funding includes a BU CTSI pilot award to study disparities in buprenorphine quality indicators among BMC patients and a contract with the Wisconsin Department of Health Services to evaluate the impact of a Section 1115 waiver on health care utilization and outcomes among Medicaid beneficiaries.
Websites
Education
- Harvard University, AB
- University of Texas Medical Branch, MD/PhD
Publications
- Published on 5/17/2024
Tilhou A, Baldwin M, Alves J. No Time to Wait: Leveraging Primary Care to Treat Stimulant Use Disorder. Am J Prev Med. 2024 Sep; 67(3):464-469. PMID: 38762205.
Read at: PubMed - Published on 4/1/2024
Tilhou AS, Dague L, Chachlani P, Burns M. Can telehealth expansion boost health care utilization specifically for patients with substance use disorders relative to patients with other types of chronic disease? PLoS One. 2024; 19(4):e0299397. PMID: 38557607.
Read at: PubMed - Published on 3/17/2024
Tilhou AS, Burns M, Chachlani P, Chen Y, Dague L. How Does Telehealth Expansion Change Access to Healthcare for Patients With Different Types of Substance Use Disorders? Subst Use Addctn J. 2024 Jul; 45(3):473-485. PMID: 38494728.
Read at: PubMed - Published on 1/2/2024
Tilhou AS, Jain A, DeLeire T. Telehealth Expansion, Internet Speed, and Primary Care Access Before and During COVID-19. JAMA Netw Open. 2024 Jan 02; 7(1):e2347686. PMID: 38180762.
Read at: PubMed - Published on 12/28/2023
Tilhou AS, Zaborek J, Baltes A, Salisbury-Afshar E, Malicki J, Brown R. Association of Fentanyl Test Strip Use, Perceived Overdose Risk, and Naloxone Possession among People Who Use Drugs. Subst Use Misuse. 2024; 59(2):254-257. PMID: 37807227.
Read at: PubMed - Published on 10/13/2023
Tilhou AS, Murray E, Wang J, Linas BP, White L, Samet JH, LaRochelle M. Trends in buprenorphine dosage and days supplied for new treatment episodes for opioid use disorder, 2010-2019. Drug Alcohol Depend. 2023 Nov 01; 252:110981. PMID: 37839942.
Read at: PubMed - Published on 10/8/2023
Alyssa S Tilhou, Jen Zaborek, Amelia Baltes, Elizabeth Salisbury-Afshar, Julia Malicki Randall Brown. Association of Fentanyl Test Strip Use, Perceived Overdose Risk, and Naloxone Possession among People Who Use Drugs. Substance Use & Misuse. 2023; (1-4).
- Published on 8/26/2023
Tilhou AS, Saloner B, DeLeire T, Chakraborty S, Dague L. Health and Healthcare Access for Essential, Nonessential, and Nonworkers During the COVID-19 Pandemic. J Occup Environ Med. 2023 Nov 01; 65(11):e703-e709. PMID: 37641177.
Read at: PubMed - Published on 3/28/2023
Tilhou AS, Zaborek J, Baltes A, Salisbury-Afshar E, Malicki J, Brown R. Differences in drug use behaviors that impact overdose risk among individuals who do and do not use fentanyl test strips for drug checking. Harm Reduct J. 2023 Mar 28; 20(1):41. PMID: 36978170.
Read at: PubMed - Published on 3/28/2023
Tilhou AS, Zaborek J, Baltes A, Salisbury-Afshar E, Malicki J, Brown R. Differences in drug use behaviors that impact overdose risk among individuals who do and do not use fentanyl test strips for drug checking. Harm Reduct J. 2023 Mar 28; 20(1):41. PMID: 36978170.
Read at: PubMed
View 8 more publications: View full profile at BUMC